Drug Profile


Alternative Names: LCQ 908; LCQ908-NXA; LCQ908A; Pradigastat sodium

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Aminopyridines; Antihyperglycaemics; Antihyperlipidaemics; Cyclohexanecarboxylic acids; Obesity therapies; Small molecules
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperlipoproteinaemia type I
  • No development reported Coronary artery disease; Hyperlipoproteinaemia type V; Hyperlipoproteinaemias; Non-alcoholic fatty liver disease; Obesity; Type 2 diabetes mellitus
  • Discontinued Hepatitis C

Most Recent Events

  • 11 Sep 2015 No recent reports on development identified - Phase-I/II for Hyperlipoproteinaemia type V in Canada (PO)
  • 12 May 2015 Phase-III is still ongoing for Hyperlipoproteinaemia type I in the United Kingdom, Spain, Canada, Netherlands and Germany
  • 01 May 2014 Novartis completes a phase III trial in Hyperlipoproteinaemia type I in the US, Canada, France, Germany, the Netherlands, South Africa, Spain and the UK (NCT01514461)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top